Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Apr 28;64(1):85–88. doi: 10.1136/ard.2003.019695

Contribution of polymorphisms in the apolipoprotein AI-CIII-AIV cluster to hyperlipidaemia in patients with gout

F Cardona 1, F Tinahones 1, E Collantes 1, A Escudero 1, E Garcia-Fuentes 1, F Soriguer 1
PMCID: PMC1755175  PMID: 15115711

Abstract

Background: Studies have shown that hyperuricaemia is independently related to the insulin resistance syndrome and that polymorphisms of the apolipoprotein AI-CIII-AIV cluster are also related to insulin resistance.

Objective: To study the prevalence of polymorphisms of the apolipoprotein AI-CIII-AIV cluster in persons with gout and to determine whether these polymorphisms contribute to the pathophysiology of gout or to altered lipid concentrations.

Methods: Plasma cholesterol, triglycerides, uric acid, VLDL, LDL, IDL, and HDL triglycerides, cholesterol, and the renal excretion of uric acid were measured in 68 patients with gout with gout and 165 healthy subjects. Polymorphisms were studied by amplification and RFLP in all subjects, using XmnI and MspI in the apolipoprotein AI gene and SstI in the apolipoprotein CIII gene.

Results: The A allele at position –75 bp in the apolipoprotein AI gene was more common in patients with gout than in controls (p = 0.01). Levels of cholesterol, triglycerides, uric acid, basal glycaemia, and HDL cholesterol were higher in the patients (p<0.001). In the patients there was also an interaction between mutations at the two polymorphic loci studied in the apolipoprotein AI gene (p = 0.04). An absence of the mutation at position –75 bp of the apolipoprotein AI gene resulted in increased plasma triglyceride levels.

Conclusions: Gouty patients have an altered allelic distribution in the apolipoprotein AI-CIII-AIV cluster, which could lead to changes in levels of lipoproteins. This is not caused by a single mutation but rather by a combination of different mutations.

Full Text

The Full Text of this article is available as a PDF (68.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barre D. E., Guerra R., Verstraete R., Wang Z., Grundy S. M., Cohen J. C. Genetic analysis of a polymorphism in the human apolipoprotein A-I gene promoter: effect on plasma HDL-cholesterol levels. J Lipid Res. 1994 Jul;35(7):1292–1296. [PubMed] [Google Scholar]
  2. Cardona F., Tinahones F. J., Collantes E., Escudero A., García-Fuentes E., Soriguer F. J. The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates. Rheumatology (Oxford) 2003 Mar;42(3):468–472. [PubMed] [Google Scholar]
  3. Civeira F., Pocovi M., Cenarro A., Garces C., Ordovas J. M. Adenine for guanine substitution -78 base pairs 5' to the apolipoprotein (APO) A-I gene: relation with high density lipoprotein cholesterol and APO A-I concentrations. Clin Genet. 1993 Dec;44(6):307–312. doi: 10.1111/j.1399-0004.1993.tb03906.x. [DOI] [PubMed] [Google Scholar]
  4. Dallinga-Thie G. M., Bu X. D., van Linde-Sibenius Trip M., Rotter J. I., Lusis A. J., de Bruin T. W. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res. 1996 Jan;37(1):136–147. [PubMed] [Google Scholar]
  5. Dallinga-Thie G. M., van Linde-Sibenius Trip M., Rotter J. I., Cantor R. M., Bu X., Lusis A. J., de Bruin T. W. Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes. J Clin Invest. 1997 Mar 1;99(5):953–961. doi: 10.1172/JCI119260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dammerman M., Sandkuijl L. A., Halaas J. L., Chung W., Breslow J. L. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4562–4566. doi: 10.1073/pnas.90.10.4562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Danek G. M., Valenti M., Baralle F. E., Romano M. The A/G polymorphism in the -78 position of the apolipoprotein A-I promoter does not have a direct effect on transcriptional efficiency. Biochim Biophys Acta. 1998 May 29;1398(1):67–74. doi: 10.1016/s0167-4781(98)00029-3. [DOI] [PubMed] [Google Scholar]
  8. Facchini F., Chen Y. D., Hollenbeck C. B., Reaven G. M. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991 Dec 4;266(21):3008–3011. [PubMed] [Google Scholar]
  9. Ferns G. A., Stocks J., Ritchie C., Galton D. J. Genetic polymorphisms of apolipoprotein C-III and insulin in survivors of myocardial infarction. Lancet. 1985 Aug 10;2(8450):300–303. doi: 10.1016/s0140-6736(85)90350-2. [DOI] [PubMed] [Google Scholar]
  10. Folsom A. R., Burke G. L., Ballew C., Jacobs D. R., Jr, Haskell W. L., Donahue R. P., Liu K. A., Hilner J. E. Relation of body fatness and its distribution to cardiovascular risk factors in young blacks and whites. The role of insulin. Am J Epidemiol. 1989 Nov;130(5):911–924. doi: 10.1093/oxfordjournals.aje.a115424. [DOI] [PubMed] [Google Scholar]
  11. GERTLER M. M., GARN S. M., LEVINE S. A. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med. 1951 Jun;34(6):1421–1431. doi: 10.7326/0003-4819-34-6-1421. [DOI] [PubMed] [Google Scholar]
  12. Groenendijk M., Cantor R. M., De Bruin T. W., Dallinga-Thie G. M. New genetic variants in the apoA-I and apoC-III genes and familial combined hyperlipidemia. J Lipid Res. 2001 Feb;42(2):188–194. [PubMed] [Google Scholar]
  13. Iribarren C., Sharp D. S., Curb J. D., Yano K. High uric acid: a metabolic marker of coronary heart disease among alcohol abstainers. J Clin Epidemiol. 1996 Jun;49(6):673–678. doi: 10.1016/0895-4356(96)00034-0. [DOI] [PubMed] [Google Scholar]
  14. Jeenah M., Kessling A., Miller N., Humphries S. G to A substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI and high density lipoprotein cholesterol concentrations. Mol Biol Med. 1990 Jun;7(3):233–241. [PubMed] [Google Scholar]
  15. Kessling A. M., Horsthemke B., Humphries S. E. A study of DNA polymorphisms around the human apolipoprotein AI gene in hyperlipidaemic and normal individuals. Clin Genet. 1985 Oct;28(4):296–306. doi: 10.1111/j.1399-0004.1985.tb00403.x. [DOI] [PubMed] [Google Scholar]
  16. López-Miranda J., Jansen S., Ordovas J. M., Salas J., Marín C., Castro P., Ostos M. A., Cruz G., López-Segura F., Blanco A. Influence of the SstI polymorphism at the apolipoprotein C-III gene locus on the plasma low-density-lipoprotein-cholesterol response to dietary monounsaturated fat. Am J Clin Nutr. 1997 Jul;66(1):97–103. doi: 10.1093/ajcn/66.1.97. [DOI] [PubMed] [Google Scholar]
  17. Meng Q. H., Pajukanta P., Valsta L., Aro A., Pietinen P., Tikkanen M. J. Influence of apolipoprotein A-1 promoter polymorphism on lipid levels and responses to dietary change in Finnish adults. J Intern Med. 1997 May;241(5):373–378. doi: 10.1046/j.1365-2796.1997.122139000.x. [DOI] [PubMed] [Google Scholar]
  18. Miller S. A., Dykes D. D., Polesky H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988 Feb 11;16(3):1215–1215. doi: 10.1093/nar/16.3.1215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Modan M., Halkin H., Karasik A., Lusky A. Elevated serum uric acid--a facet of hyperinsulinaemia. Diabetologia. 1987 Sep;30(9):713–718. doi: 10.1007/BF00296994. [DOI] [PubMed] [Google Scholar]
  20. Ordovas J. M., Civeira F., Genest J., Jr, Craig S., Robbins A. H., Meade T., Pocovi M., Frossard P. M., Masharani U., Wilson P. W. Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis. 1991 Mar;87(1):75–86. doi: 10.1016/0021-9150(91)90234-t. [DOI] [PubMed] [Google Scholar]
  21. Perez-Ruiz F., Calabozo M., Erauskin G. García, Ruibal A., Herrero-Beites A. M. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum. 2002 Dec 15;47(6):610–613. doi: 10.1002/art.10792. [DOI] [PubMed] [Google Scholar]
  22. Queipo-Ortuño M. I., Garcia-Ordoñez M. A., Colmenero J. D., Morata P. Hydrogen peroxide improves the efficiency of a peripheral blood PCR assay for diagnosis of human brucellosis. Biotechniques. 1999 Aug;27(2):248-50, 252. doi: 10.2144/99272bm06. [DOI] [PubMed] [Google Scholar]
  23. Quiñones Galvan A., Natali A., Baldi S., Frascerra S., Sanna G., Ciociaro D., Ferrannini E. Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995 Jan;268(1 Pt 1):E1–E5. doi: 10.1152/ajpendo.1995.268.1.E1. [DOI] [PubMed] [Google Scholar]
  24. Rathmann W., Funkhouser E., Dyer A. R., Roseman J. M. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol. 1998 May;8(4):250–261. doi: 10.1016/s1047-2797(97)00204-4. [DOI] [PubMed] [Google Scholar]
  25. Rathmann W., Hauner H., Dannehl K., Gries F. A. Association of elevated serum uric acid with coronary heart disease in diabetes mellitus. Diabete Metab. 1993;19(1 Pt 2):159–166. [PubMed] [Google Scholar]
  26. Reaven G. M., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996 Feb 8;334(6):374–381. doi: 10.1056/NEJM199602083340607. [DOI] [PubMed] [Google Scholar]
  27. Selby J. V., Friedman G. D., Quesenberry C. P., Jr Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol. 1990 Jun;131(6):1017–1027. doi: 10.1093/oxfordjournals.aje.a115593. [DOI] [PubMed] [Google Scholar]
  28. Shoulders C. C., Narcisi T. M., Jarmuz A., Brett D. J., Bayliss J. D., Scott J. Characterization of genetic markers in the 5'flanking region of the apo A1 gene. Hum Genet. 1993 Mar;91(2):197–198. doi: 10.1007/BF00222727. [DOI] [PubMed] [Google Scholar]
  29. Soriguer-Escofet Federico, Esteva Isabel, Rojo-Martinez Gemma, Ruiz de Adana Soledad, Catalá Marieta, Merelo M. José, Aguilar Manuel, Tinahones Francisco, García-Almeida José M., Gómez-Zumaquero Juan M. Prevalence of latent autoimmune diabetes of adults (LADA) in Southern Spain. Diabetes Res Clin Pract. 2002 Jun;56(3):213–220. doi: 10.1016/s0168-8227(02)00002-5. [DOI] [PubMed] [Google Scholar]
  30. Tinahones F. J., Collantes E., C-Soriguer F. J., González-Ruiz A., Pineda M., Añn J., Sánchez Guijo P. Increased VLDL levels and diminished renal excretion of uric acid in hyperuricaemic-hypertriglyceridaemic patients. Br J Rheumatol. 1995 Oct;34(10):920–924. doi: 10.1093/rheumatology/34.10.920. [DOI] [PubMed] [Google Scholar]
  31. Tinahones F. J., Collantes E., C-Soriguer F. J., González-Ruiz A., Pineda M., Añn J., Sánchez Guijo P. Increased VLDL levels and diminished renal excretion of uric acid in hyperuricaemic-hypertriglyceridaemic patients. Br J Rheumatol. 1995 Oct;34(10):920–924. doi: 10.1093/rheumatology/34.10.920. [DOI] [PubMed] [Google Scholar]
  32. Tinahones J. F., Pérez-Lindón G., C-Soriguer F. J., Pareja A., Sánchez-Guijo P., Collantes E. Dietary alterations in plasma very low density lipoprotein levels modify renal excretion of urates in hyperuricemic-hypertriglyceridemic patients. J Clin Endocrinol Metab. 1997 Apr;82(4):1188–1191. doi: 10.1210/jcem.82.4.3866. [DOI] [PubMed] [Google Scholar]
  33. Vuorinen-Markkola H., Yki-Järvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab. 1994 Jan;78(1):25–29. doi: 10.1210/jcem.78.1.8288709. [DOI] [PubMed] [Google Scholar]
  34. Wang X. L., Badenhop R., Humphrey K. E., Wilcken D. E. C to T and/or G to A transitions are responsible for loss of a MspI restriction site at the 5'-end of the human apolipoprotein AI gene. Hum Genet. 1995 Apr;95(4):473–474. doi: 10.1007/BF00208984. [DOI] [PubMed] [Google Scholar]
  35. Wang X. L., Badenhop R., Humphrey K. E., Wilcken D. E. New MspI polymorphism at +83 bp of the human apolipoprotein AI gene: association with increased circulating high density lipoprotein cholesterol levels. Genet Epidemiol. 1996;13(1):1–10. doi: 10.1002/(SICI)1098-2272(1996)13:1<1::AID-GEPI1>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  36. Wang X. L., Liu S. X., McCredie R. M., Wilcken D. E. Polymorphisms at the 5'-end of the apolipoprotein AI gene and severity of coronary artery disease. J Clin Invest. 1996 Jul 15;98(2):372–377. doi: 10.1172/JCI118802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Waterworth D. M., Ribalta J., Nicaud V., Dallongeville J., Humphries S. E., Talmud P. ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests. Circulation. 1999 Apr 13;99(14):1872–1877. doi: 10.1161/01.cir.99.14.1872. [DOI] [PubMed] [Google Scholar]
  38. Xu C. F., Angelico F., Del Ben M., Humphries S. Role of genetic variation at the apo AI-CIII-AIV gene cluster in determining plasma apo AI levels in boys and girls. Genet Epidemiol. 1993;10(2):113–122. doi: 10.1002/gepi.1370100204. [DOI] [PubMed] [Google Scholar]
  39. Zavaroni I., Mazza S., Fantuzzi M., Dall'Aglio E., Bonora E., Delsignore R., Passeri M., Reaven G. M. Changes in insulin and lipid metabolism in males with asymptomatic hyperuricaemia. J Intern Med. 1993 Jul;234(1):25–30. doi: 10.1111/j.1365-2796.1993.tb00700.x. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES